Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

The ongoing evolution of Medical Affairs

April 14, 2023 | #COVID19, AI, Eddie Power, Healthcare Technology, Impetus Digital, Medical Affairs Pharma, Medical Affairs Teams, Natalie Yeadon, Pfizer, bioethics, blockchain, data privacy, machine learning, medical affairs, pharma technology, silico trials 

In the latest episode of Impetus Digital’s Fireside Chat series, Natalie Yeadon, Co-Founder and CEO of Impetus Digital talks to Eddie Power, Vice President of North America Medical Affairs, Hospital Business at Pfizer.They discuss a range of topics, including the effects of COVID-19 on the way Medical Affairs teams work and interact with the healthcare community. They also delve into the concept of ‘systems thinking’ and how this line of thinking can be applied within Medical Affairs and Pharma as a whole. Further, Eddie gives his thoughts on the role of technology in applying systems thinking, including barriers such as concerns about data privacy and bioethics. Other topics explored include innovative concepts such as in silico trials, AI and machine learning, and blockchain.

This content was provided by Impetus Digital

Company Details

- PMLiVE

Impetus Digital

Email
Website

 Latest Content from  Impetus Digital 

Tailored Marketing Strategies for Pharma – Top 10 Most Important Advisor Questions

In this video, we explore another crucial aspect of advisor questions when developing your virtual advisory board touchpoints – a key component for success in today’s diverse healthcare landscape. 7….

Trends in Virtual Collaboration

Join us for a look at the top-5 emerging virtual collaboration trends…

Advisor Questions on Potential Data or Knowledge Gaps

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here’s another one to keep in…

On a journey to diverse, inclusive, and more efficient rare disease trials

Although orphan drugs represent a sizeable portion of new drug approvals, most rare diseases still lack effective treatment. Even more so than for other conditions, rare disease management contains large care…

Versatility! Top 10 benefits of virtual advisory boards

Here’s another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #10. Versatility! Another major advantage of using a virtual platform…

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story

In the early lead-up to our client’s multi-center Rare Disease Phase 3 Clinical Trial, they first conducted an internal engagement planning Longitudinal Expert Engagement Plan™ (LEEP™) to conduct an informal…

New Playbook Alert: Virtual Patient Engagement

Authentic patient engagement and insight-gathering are becoming must-haves in Pharma. However, multiple obstacles remain before patient-centricity becomes more than a buzzword. In our latest playbook, we take a deep dive…

No “White Space” Between Live Meetings; the top 10 benefits of virtual advisory boards

Here’s another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #9. No More “White Space” Between Live Meetings Clearly, the…

The problem with clinical trials (and how virtual insight-gathering can help)

While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access.

Ease and Effectiveness of Knowledge Sharing; the top 10 benefits of virtual advisory boards

Here’s another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #8. The Ease and Effectiveness of Sharing Knowledge and Data…